Cohance Lifesciences credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

170	170	78.1	38.6	69.2	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−156	−156	−202	−786	−418
0.04×	0.04×	0.04×	0.02×	0.04×
−0.04×	−0.04×	−0.11×	−0.38×	−0.24×
0.40×	0.40×	0.21×	0.10×	0.12×
−0.49×	−0.37×	−0.54×	−1.94×	−0.74×
6.44×	6.44×	24.11×	47.14×	95.43×
4.0%	4.0%	4.1%	1.8%	3.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	69.2	38.6	78.1	169.7	169.7
Net Debt	-417.8	-785.8	-202.3	-156.3	-156.3
Total Debt/Equity	0.04	0.02	0.04	0.04	0.04
Net Debt/Equity	-0.24	-0.38	-0.11	-0.04	-0.04
Total Debt/EBITDA	0.12	0.10	0.21	0.40	0.40
Net Debt/EBITDA	-0.74	-1.94	-0.54	-0.37	-0.49
Interest Coverage (EBIT/Interest)	95.43	47.14	24.11	6.44	6.44
Total Debt/Total Capital %	3.83	1.85	4.07	4.04	4.04

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.